Nxera Pharma Notes Successful Development Progress of
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with ...
Read moreNBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with ...
Read morePIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid ...
Read moreEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset ...
Read moreLONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing ...
Read moreNxera Pharma to represent WODA in Japan and South Korea WODA offers a ‘one-stop’ solution for biopharma companies seeking to ...
Read more- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, ...
Read moreNew name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by ...
Read moreVIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management ...
Read moreCORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached ...
Read morePactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.